SCHEMBL28622702

SCHEMBL28622702

COC(=O)[C@H](CCS)NC(=O)OC(C)(C)C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC4 P56524 3/20 0.46
HDAC1 Q13547 3/20 0.46
HDAC6 Q9UBN7 1/20 0.46
CTSK P43235 10/20 0.44
CTSS P25774 6/20 0.44
CYP1A2 P05177 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
HTT P42858 1/20 0.43
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA7 P43166 1/20 0.42
CTSL P07711 2/20 0.41
CTSB P07858 1/20 0.41
NFKB1 P19838 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
KLK5 Q9Y337 1/20 0.41
CA12 O43570 1/20 0.40
CA14 Q9ULX7 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10311801 1.00 HDAC4 (0.46) HDAC4HDAC1HDAC6CTSKCTSS
SCHEMBL474893 0.92 HDAC4 (0.47) HDAC4HDAC1HDAC6CTSKCTSS
SCHEMBL30788769 0.92 HDAC4 (0.47) HDAC4HDAC1HDAC6CTSKCTSS
SCHEMBL474895 0.92 HDAC4 (0.47) HDAC4HDAC1HDAC6CTSKCTSS
SCHEMBL6446073 0.87 CYP1A2 (0.58) HDAC4HDAC1HDAC6CTSKCTSS
SCHEMBL6446074 0.87 CYP1A2 (0.58) HDAC4HDAC1HDAC6CTSKCTSS
SCHEMBL295886 0.86 CYP1A2 (0.46) HDAC4HDAC1HDAC6CTSKCTSS
SCHEMBL1341495 0.86 CYP1A2 (0.46) HDAC4HDAC1HDAC6CTSKCTSS
SCHEMBL3819517 0.86 CYP1A2 (0.46) HDAC4HDAC1HDAC6CTSKCTSS
SCHEMBL24299005 0.85 CTSK (0.46) CTSKCTSSCYP1A2CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260034094-A1 COMPOSITIONS AND METHODS FOR INDUCING FERROPTOSIS KOJIN THERAPEUTICS INC (US) 2026-02-05 US disclosed
EP-4565228-A2 COMPOSITIONS AND METHODS FOR INDUCING FERROPTOSIS Kojin Therapeutics, Inc. (US) 2025-06-11 EP disclosed
WO-2025021833-A1 MULTIVALENT CARGO-CARRYING COMPLEXES AND USES THEREOF ASTRAZENECA AB (SE) 2025-01-30 WO disclosed
WO-2024030960-A2 COMPOSITIONS AND METHODS FOR INDUCING FERROPTOSIS Kojin Therapeutics, Inc. (US) 2024-02-08 WO disclosed
CN-113214043-B Method for efficiently preparing deuterated methyl iodide and application thereof 云南民族大学 2024-02-06 CN disclosed
US-20220160905-A1 FLUORINATION METHOD OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2022-05-26 US disclosed
CN-113214043-A Method for efficiently preparing deuterated iodomethane and application thereof 云南民族大学 2021-08-06 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220160905-A1 FLUORINATION METHOD AFF2, AFF1, AFF4 HDAC4 4143/4885HDAC1 4060/4885HDAC6 960/4885
US-20260034094-A1 COMPOSITIONS AND METHODS FOR INDUCING FERROPTOSIS AIFM2, GPX4, HMOX1 HDAC4 1576/4885HDAC1 1323/4885HDAC6 1640/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.